In the current trading session, Kymera Therapeutics Inc. (KYMR) stock shares had surged by 3.75% to trade at the price of $46.04 at last check. KYMR stock had previously closed down the session at the share price of $44.38. The KYMR stock volume traded 73906.0 shares, while the average daily volume of KYMR stock trade is 0.4 million shares for the past 50 days. KYMR shares have moved down in the past week by -6.27%. In the past three and six months, the KYMR stock has gained 16.67%, and however shed -44.92% respectively. Furthermore, Kymera Therapeutics Inc. is currently valued in the market at a total of $1.99 billion and has 44.65 million in total outstanding shares.
Here’s what you need to know about Kymera Therapeutics Inc.
Kymera Therapeutics is a biopharma and biotech company that specifically focuses on the manufacturing and designing of therapeutics for unmet medical needs. The company’s operational platform is for the discovery and development of treatment against disease-causing proteins through small molecule therapeutics. This small molecule therapeutics have the ability to assist the body’s natural protein degradation tendencies in its system.
The KYMR stock has programs in its pipeline which include the treatment of immunology-inflammation diseases through the development of its treatment product known as IRAK4 program which is in phase I clinical trial and includes treatment of hidradenitis suppurative, atopic dermatitis and rheumatoid arthritis.
IRAKMiD program is used for the treatment of MYD88-mutated B cell lymphoma which are diffuse and large. The STAT3 program is being carried out for the hemtologic malignancy cures and solid tumors, along with autoimmune diseases. The company was established in 2015 and is based in Watertown, Massachusetts.
Kymera Therapeutics has displayed positive interim data for its single dose of KT-474 in phase 1 trial
One of KYMR stock’s leading candidates included the KT-474 program which has recently displayed positive interim results. The phase 1 trial of the single ascending dose of KT showed that the drug exceeded beyond the 85% target degradation and achieved success within the SAD portion of 90% median degradation at 300mg dose.
Kymera did not observe any adverse effects during this trial study on any level of the dose. All doses were administered as a single administration. These observations reflected the efficacy and safety of the targeted degradation of protein which also displays proof of mechanism as required by the FDA. This safety and efficacy display has allowed FDA to confide in the proof of mechanism and allow for the uplifting of a partial clinical hold on the Multiple Ascending Dose portion of the Phase 1 trial. Kymera will take full advantage of this access and will also plan to repeat dosing in the next month.